The somatic affairs of BRAF: Tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations

Journal of Clinical Pathology

Volumn 66, Issue 5, 2013, Pages 441-445

  Ponti, Giovanni ^a   Pellacani, Giovanni ^a   Tomasi, Aldo ^a   Gelsomino, Fabio ^b   Spallanzani, Andrea ^b   Depenni, Roberta ^b   Al Jalbout, Samer ^a   Simi, Lisa ^c   Garagnani, Lorella ^b   Borsari, Stefania ^a   Conti, Andrea ^a   Ruini, Cristel ^a   Fontana, Annalisa ^b   Luppi, Gabriele ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; DABRAFENIB; VEMURAFENIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG INDUCED HEADACHE; DRUG TOLERANCE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NODULE; LYMPH NODE DISSECTION; MALE; MELANOMA; NAUSEA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENTINEL LYMPH NODE METASTASIS; SOMATIC MUTATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; COMPASSIONATE USE TRIALS; FEMALE; HUMANS; IMIDAZOLES; INDOLES; MALE; MELANOMA; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM STAGING; OXIMES; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84876766091     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-201345     Document Type: Article

References (19)

1. Kefford R, Arkenau H, Brown MP, et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010;28(Suppl.; abstr.8503): 611s.
2. Catalogue of somatic mutation in cancer (COSMIC). http://www.sanger.ac. uk/cosmic (accessed 1 Dec 2012).
3. Vultur A, Villanueva J, Herlyn M. Targeting BRAF in advanced melanoma: a first step toward manageable disease. Clin Cancer Res 2011;17: 1658-63.
4. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380: 358-65.
5. Ascierto PA, Kirwood JM, Grob JJ, et al. The role of BRAF V600 mutation in melanoma. Journal of Translation Medicine 2012;10: 85.
6. Little AS, Smith PD, Cook SJ. Mechanisms of acquired resistance to ERK1/2 pathway inhibitors. Oncogene 2012 May 7. doi: 10.1038/onc.2012.160. [Epub ahead of print].
7. Nazarian R, Shi HB, Wang Q, et al. Melanomas acquire resistance to BRAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468: 973-U377.
8. Shi H, Kong X, Ribas A, et al. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res 2011;71: 5067-74.
9. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468: 973-7.
10. Horstmann E, McCabe MS, Grochow L, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 2005;352: 895-904. (Pubitemid 40300298)
11. El-Osta H, Falchook G, Tsimberidou A, et al. BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One 2011;6:e25806.
12. Janku F, Wheler JJ, Westin SN, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012;30: 777-82.
13. Benlloch S, Paya A, Alenda C, et al. Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology. J Mol Diagn 2006;8: 540-3. (Pubitemid 44774151)
14. Schoenewolf NL, Dummer R, Mihic-Probst D, et al. Detecting BRAF mutations in formalin-fixed melanoma: experiences with two state-of-the-art techniques. Case Rep Oncol 2012;5: 280-9.
15. Anderson S, Bloom KJ, Vallera DU, et al. Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed paraffin-embedded tissue specimens of malignant melanoma. Arch Pathol Lab Med 2012;136: 1385-91.
16. Ney JT, Froehner S, Roesler A, et al. High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS, BRAF, PIK3CA, and AKT1 mutations in formalin-fixed, paraffin-embedded tissues. Arch Pathol Lab Med 2012;136: 983-92.
17. Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol 2013;37: 61-5.
18. Wilmott JS, Tembe V, Howle JR, et al. Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. Mol Cancer Ther 2012;11: 2704-8.
19. Ponti G, Tomasi A, Pellacani G. Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma. J Hematol Oncol 2012;5: 60.